de Dios HD

Language: Spanish
References: 16
Page: 1-10
PDF size: 705.89 Kb.

ABSTRACT

Introduction: breast cancer has increased by 50% in the last two decades. Cathepsin B is a protease involved in the process of tumorigenesis. One of the current problems is the emergence of drug resistance. The search for new therapeutic alternatives can reduce its morbidity and mortality.
Objective: in-silico structural and functional characterization of the conserved region in Cathepsin B as a potential therapeutic target in the treatment of breast cancer.
Methods: using the NCBI ENTREZ tool 2,485 Cathepsin B sequences were obtained. The sequences were subjected to multiple alignments using Clustall Omega 1.2.4. Structural and functional characterization of the protease under study was performed using the InterPro, Prosite, Uniprot and UniprotKB databases. Using the Jalview viewer, the largest conserved area of Cathepsin B species was chosen.
Results: the protease is involved in the regulation of catalytic activity, proteolysis, negative regulation of cell death, collagen catabolic processes and possesses hydrolase activity. The multiple analyses allowed the visualization of the aminoacid characteristics of the active site of Cathepsin B and the selection of the most conserved protein region.
Conclusions: the conserved region of Cathepsin B constitutes a potential target in the development of inhibitors as drugs against breast cancer. In-silico analysis reduces the cost of current research and contributes to pharmacological biosafety.

REFERENCES

1. Waks A, Winer E. Breast cancer treatment a review. Rev Clinical Review and Education [Internet]. 2019 [citado: 11/03/2021]; 321(3): [aprox. 3p.]. Disponible en: Disponible en: http://bdrc.tums.ac.ir/uploads/140/2020/Jun/17/Breast-Cancer-Treatment-Jan-2019-1.pdf

2. Bray F, Piñeros M. Patrones, tendencias y proyecciones del cáncer en América Latina y el Caribe: un contexto global. Salud Pública Mex [Internet]. 2016 [citado 07/03/2021]; 58(2): [aprox. 7p.]. Disponible en: Disponible en: https://www.medigraphic.com/pdfs/salpubmex/sal-2016/sal162d.pdf

3. Ramírez Valle M, García Montesino G, Lores Hechevarria C, Sánchez Azcuy Y, Márquez Hernández C. Histología e inmunohistoquímica del cáncer de mama invasivo en la provincia de Pinar del Río. Rev. cienc. méd. Pinar Río [Internet]. 2019 [citado: 07/03/2021]; 23(1): 71-78. Disponible en: Disponible en: http://revcmpinar.sld.cu/index.php/publicaciones/article/view/3801

4. Ministerio de Salud Pública. Anuario estadístico 2018 [Internet]. 2019. La Habana. MINSAP. Disponible en: http://www.onei.gob.cu/sites/default/files/aec_2019_0.pdf

5. Samira Jaeger, Ana Igea, Rodrigo Arroyo, Victor Alcalde, Begoña Canovas, Modesto Orozco, et al. Quantification of pathway crosstalk reveals novel synergistic drug combinations for breast cancer. Rev Cancer Research [Internet]. 2017 [citado: 07/03/2021]; 77(2): 459-469. Disponible en: Disponible en: https://cancerres.aacrjournals.org/content/77/2/459

6. Aggarwal N, Sloane B. Cathepsin B: Multiple roles in cancer. Rev Proteomics Clin. Appl [Internet]. 2014 [citado: 07/03/2021]; 8(5): 427-437. Disponible en: Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1002/prca.201300105

7. Gondi C, Rao J. Cathepsin B as a cancer target. Rev Expert Opin Ther Targets [Internet]. 2013 [citado: 07/03/2021]; 17(3): 281-291. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587140/

8. Naranjo Feliciano D. Análisis in silico de la catepsina B de Fasciola hepática como diana terapéutica. REDVET [Internet]. 2009 [citado: 08/03/2021]; 10(2): 1-36. Disponible en: Disponible en: http://www.redalyc.org/articulo.oa?id=63617114011

9. 9 . Nelson D, Cox M. Aminoácidos, péptidos y proteínas. En: Freeman WH, eds. Lehninger Principios de Bioquímica. 5ta ed. Barcelona: Omega; 2009.

10. Li Y, Fang J, Zhen G. Cathepsin B and L inhibitors: a patent review (2010 - present). Expert Opinion on Therapeutic Patents [Internet]. 2017 [citado: 11/03/2021]; 27(6): 643-656. Disponible en: Disponible en: https://www.tandfonline.com/doi/abs/10.1080/13543776.2017.1272572

11. Garg S, Raghav N. Inhibitory potential of some chalcones on cathepsins B, H and L. RCS Adv [Internet]. 2015 [citado: 08/03/2021]; 5: 72937-72949. Disponible en: Disponible en: https://www.readcube.com/articles/10.1039%2Fc5ra12856k

12. Socic I, Mitrovic A, Curic H, Knez D, Brodnik H, Stefane B, et al. Cathepsin B inhibitors: Further exploration of the nitroxoline core. Bioorganic & Medicinal Chemistry Letters [Internet]. 2018 [citado: 09/03/2021]; 28(7): 1239-1247. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0960894X18301471?via%3Dihub

13. Dai Z, Cheng Q, Zhang Y. Rational design of a humanized antibody inhibitor of cathepsin B. Biochemistry [Internet]. 2020 [citado: 09/03/2021]; 59(14): 1420-1427. Disponible en: Disponible en: https://pubs.acs.org/doi/abs/10.1021/acs.biochem.0c00046

14. Toupin N, Arora K, Shrestha P, Peterson J, Fischer L, Rajagurubandara E, et al. BODIPY-caged photoactivated inhibitors of cathepsin B flip the light switch on cancer cell apoptosis. ACS Chem. Biol [Internet]. 2019 [citado: 09/03/2021]; 14(12): 2833-2840. Disponible en: Disponible en: https://pubs.acs.org/doi/abs/10.1021/acschembio.9b00711

15. Rajagopal K, Arumugasamy P, Byran G, Pandiyan B. In-silico Design, ADMET Screening, MM-GBSA Binding Free Energy of Some Novel Isoxazole Sustituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer. International Journal of Computational and Theoretical Chemistry [Internet]. 2019 [citado: 04/03/2021]; 7(1): 6-13. Disponible en: Disponible en: http://www.sciencepublishinggroup.com/journal/paperinfo?journalid=228&doi=10.11648/j.ijctc.20190701.12

16. Maruthanila V, Elancheran R, Nand R, Anupam B, AjaiKumar K, Kabilan S et al. In silico Molecular Modelling of Selected Natural Ligands and their Binding Features with Estrogen Receptor Alpha. Current Computer [Internet]. 2019 [citado: 04/03/2021]; 15(1): 89-96. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/30306879/